



www.healthaccessbridge.org

GPC+ Meeting


Updates on Long Acting PrEP

October 05, 2026

Access Bridge is an independent, Africa-anchored organization advancing timely, sustainable, and equitable introduction of and access to HIV prevention and related health products by providing the leadership, coordination, data, and actionable insights needed to translate innovation into real-world impact where it is needed most.




Current LEN for PrEP Supply



LEN rollout is advancing rapidly, with strong demand and preference, but supply and delivery constraints could limit 2027 scale-up

Current PrEP Pipeline




An expanding PrEP toolbox creates new opportunity, but realizing its full potential will require addressing persistent financing, delivery and system constraints.

Long-Acting PrEP Generic License Coverage


Gilead has licensed six generic manufacturers, with initial supply expected in early 2027, but the licences exclude several high-burden countries in Latin America and Asia.

COUNTRY TOTAL BY PRODUCT

Alimatravir (AMI): 129 | Lenacapavir (LEN): 120 | Cabotegravir (CAB): 90*




**CAB can also be sold in an additional 43 countries that do not have patent barriers*



Alimatravir (AMI) Licensing Timeline

Merck/MSD announced initial voluntary license agreements with seven generic manufacturers to produce its investigational monthly oral PrEP candidate, alimatravir, well ahead of efficacy trial results. This builds on years of advocacy to shorten the timeline between scientific breakthroughs and public health impact.



Three of the generic manufacturers are in Africa (Kenya, Uganda and South Africa). AMI efficacy results expected in late 2027.



Transitioning LA PrEP Coalition into GPC+

1. Protect continuity of urgent LEN and pipeline product introduction functions during the GPC+ transition as we prepare for new innovations including AMI
2. Position new product introduction as part of a broader prevention support platform: country-led, community-informed, demand-driven, data-guided, and accountable.

From current pain points	Toward the GPC+ model	Access Bridge & AVAC transition contribution
Product-specific and fragmented platforms; duplication, tool/meetings fatigue, and weak integration across GPC, LA PrEP Coalition and other mechanisms.	Country and community-led prevention support architecture with clearer role delineation, multi-directional accountability, and prevention impact as the core principle.	Map Coalition assets, tools, lists, convenings and TA linkages; identify what should transition, integrate, pause, or be re-labeled.
Global priorities not always operationalized around country needs; TA can be supply-driven rather than demand-driven.	Country leadership and prevention enablement: countries lead and TA responds to demand, with practical operational support and peer learning linked to follow-through.	Maintain TA coordination, Prevention Tools & resource linkage, PrEP Connection learning, and implementation issue escalation while aligning these functions with GPC+.
Innovation readiness can remain siloed from wider prevention systems and financing realities.	New product introduction embedded in a broader platform that protects high-impact prevention, optimizes financing, and uses data/tools for decisions.	Keep LEN rollout and pipeline readiness moving while linking lessons, dashboards, industry engagement, and financing/implementation implications to GPC+ priorities.

Maintained continuity of the introduction of LA PrEP agenda during the transition to GPC+.

Converted emerging lenacapavir supply challenges into coordinated action.

Strengthened country-to-global feedback loops on early LEN introduction.

Sustained practical learning and problem-solving across the wider PrEP field.

Advanced meaningful civil society participation in the new GPC+ structure.

Strengthened engagement with product developers and global stakeholders.

Elevated implementation and access priorities at AIDS 2026. Continued development of rapid technical-support infrastructure.

Thank You!

For more information contact:

Wawira Nyagah

wawira@healthaccessbridge.org

